The Motley Fool

2 FTSE 100 stocks for retirement income AND growth

Dividend stocks are an appealing source of income for retirement. They can offer a relatively high yield and there’s the potential for the dividend to advance ahead of inflation, increasing its real value year after year.

Of course, profits must grow over time if an increasing dividend is to be sustainable. Today, I’m looking at two FTSE 100 companies which have above-average yields and which I believe are set for strong profit growth in the coming years. Such stocks tend to deliver good capital gains in addition to a high and growing dividend flow.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Five years of struggle

Long-term shareholders of AstraZeneca (LSE: AZN) have seen their company endure a difficult period over the last five years. Revenue and profits have fallen because patents have expired on some of its top-selling products opening the way for generic competition.

Despite the difficulties, Astra has at least managed to maintain its dividend — at $2.80 a share — although this has meant that its real value to shareholders has been gradually eroded by inflation. However, the good news is that the company’s fortunes are set to improve markedly in the coming years.

Chief executive Pascal Soriot has worked hard to restructure and reinvigorate the business since his arrival in 2012. His efforts are beginning to pay off and the market is beginning to appreciate the potential of the company’s robust pipeline of new drugs. For example, the announcement of positive trial results last month for its Imfinzi treatment of non-small cell lung cancer saw the shares immediately rise by more than 10%.

Growth ahead

Astra fought off a takeover bid from US giant Pfizer three years ago, saying the 5,500p a share offer undervalued the business. As part of the defence, Mr Soriot said Astra was targeting revenue of $45bn by 2023. Revenue last year was $21m, so the rate of top-line growth over the next five years will be considerable if the company is to meet its target. And that should drive strong growth in profits.

Astra’s shares are currently trading at 5,400p — just below the level of the Pfizer bid, three years on — and the $2.80 a share dividend (about 220p at current exchange rates) gives a yield of 4.1%. With the company on the cusp of powering up revenues and profits, investors can hope for a rising dividend stream and continuing appreciation of the share price.

Dominant player

In contrast to AstraZeneca, Provident Financial (LSE: PFG) has thrived over the past five years. Strong earnings growth has supported a dividend that’s increased from 77.2p a share in 2012 to 134.6p last year. The UK’s leading non-standard lender consolidated its position as conventional banks became more risk-averse and reluctant to lend in the wake of the financial crisis.

Has Provident enjoyed a boom period that’s now set to end? I don’t believe so. The company has invested heavily in its businesses and systems and is the dominant player in what is a structurally-changed lending market.

I’m anticipating profits to continue to grow strongly in the coming years. City analysts are forecasting a dividend increase of over 6% this year, followed by a double-digit percentage next year. This gives a yield of 5%, rising to 5.5% — at a current share price of 2,885p — and I see this as another stock that could add strong capital gains to its excellent income prospects.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.